WSWilson Sui

Wilson Sui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wilson Sui has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    3D MR Fingerprinting for Quantitative Bladder Wall T 1 , T 2 , and M 0 Mapping in Healthy Subjects at 1.5 T and 3 T

    by Shane A. Wells, Giulia M. Ippolito, Melis Ozkan, Wilson Sui, Anne P. Cameron, Jesse I. Hamilton

    Current diagnostic tests for lower urinary tract symptoms (LUTS) do not assess tissue‐level alterations in the bladder wall. This study assesses the feasibility of 3D magnetic resonance fingerprinting (MRF) for simultaneous T 1 , T 2 , and proton density (M 0 ) mapping of the bladder wall in healthy subjects at 1.5 T and 3 T. A 3D MRF acquisition was combined with a deep image prior reconstruction to achieve whole‐bladder T 1 , T 2 , and M 0 mapping in 11.8 min at an acquired voxel size of 1 × 1 × 3 mm 3 (interpolated to 0.5 × 0.5 × 1.5 mm 3 ). Twenty‐nine healthy subjects (14 female, 18–78 years) were enrolled, with 16 scanned at both 1.5 T and 3 T. Conventional maps were acquired using MOLLI and T 2 ‐prepared GRE sequences. Maps were analyzed by measuring mean global and regional T 1 and T 2 values, with spatial heterogeneity assessed using the coefficient of variation (CV). Bladder wall thickness (BWT) was measured from synthetic weighted images derived from MRF maps, compared to reference values from conventional T 2 ‐weighted MRI. Mean global MRF bladder wall measurements were 984 53 ms (T 1 ), 51.4 5.6 ms (T 2 ), and 4.5 1.6 mm (BWT) at 1.5 T and 1468 118 ms (T 1 ), 43.5 4.0 ms (T 2 ), and 4.3 1.6 mm (BWT) at 3 T. MRF T 1 values were significantly lower than MOLLI at 1.5 T (bias −151 ms) but not significantly different at 3 T. MRF T 2 values were significantly lower (by 7–8 ms) than T 2 ‐prepared GRE at both field strengths. MRF exhibited lower CV than MOLLI T 1 mapping at 1.5 T. BWT from synthetic images exhibited excellent agreement (bias .1 mm) with conventional T 2 ‐weighted images. Regionally, T 1 and T 2 tended to be higher in the dome and posterior wall. In an exploratory analysis, a positive association between age and T 2 was observed. In conclusion, 3D MRF of the bladder wall is feasible in healthy subjects, providing a baseline for translational studies to characterize pathological remodeling in LUTS.

  • Open Access

    Magnetic resonance fingerprinting of the bladder is feasible in men with lower urinary tract symptoms

    by Aymen Bahsoun, Jesse Hamilton, Giulia Ippolito, Christopher Brace, Chamila Perera, Wilson Sui, Jesus Fajardo, Vikas Gulani, Nicole Seiberlich, Anne Cameron, et al.

    Purpose: To quantify bladder wall relaxation times in men without and with lower urinary tract symptoms (LUTS) using three-dimensional (3D) magnetic resonance fingerprinting (MRF). Materials and methods: Following informed consent, 51 men (mean age 68.2 years, range 46–80) on active surveillance for prostate cancer underwent multiparametric MRI that included an investigational 3D MRF sequence. Anterior bladder wall T 1 and T 2 relaxation times were measured from the quantitative maps. Anterior bladder wall thickness (BWT) was measured and prostate and transition zone (TZ) volumes were estimated, from the conventional T2w images. Body mass index (BMI), LUTS scores (AUA-SI), risk factors for metabolic syndrome, history of diabetes (DM), and medications prescribed for LUTS were documented from the electronic medical record. The Kruskal-Wallis rank sum test, Wilcoxon rank sum exact test, and Fisher’s exact test were used to assess the associations between clinical variables, categorical imaging data, and mean T 1 and T 2 relaxation times. Results: Native bladder wall T 1 relaxation times were longer in men with higher AUA-SI scores [AUA-SI 0–7: 1,496 ms vs. AUA-SI 8–20: 1,787 ms vs. AUA-SI 21–35: 2,063 ms, p = 0.03] while native bladder wall T 2 relaxation times were similar [AUA-SI 0–7: 67 ms vs. AUA-SI 8–20: 78 ms vs. AUA-SI 21–35: 122 ms, p = 0.3]. Native bladder wall T 1 relaxation times were shorter in diabetic men compared to non-diabetic men (1239 ms vs. 1633 ms, p < 0.001), while T 2 relaxation times were similar (86 ms vs. 62 ms, p = 0.4). Prostate and TZ volume, and BWT were similar in men without and with LUTS and DM. Conclusion: 3D MRF of the bladder is feasible, provides in-vivo tissue characterization of the bladder wall in men with LUTS.

  • Open Access

    The association between quality of life, intensity of counseling and health literacy amongst patients with nephrolithiasis

    by Wilson Sui, Lavanya Gupta, Al Sultan Azzawi, Maria C. Velasquez, Heiko Yang, Thomas Chi, Marshall L. Stoller

    Introduction: The American Urological Association (AUA) provides guidance on primary prevention for nephrolithiasis; however, patient compliance is often poor. The role of healthy literacy in the primary prevention of nephrolithiasis is not well understood. Understanding kidney stone formers’ perceptions and knowledge of primary prevention is critical to evaluating their health literacy. This study aimed to assess these perceptions and explore how they relate to counseling intensity and quality of life among patients with nephrolithiasis. Materials and Methods: A cross-sectional web-based survey was administered to a random sample of adult volunteers. Disease specific information was queried for stone formers and all participants were asked a series of questions based on the AUA Metabolic Stone Management Guidelines (2016) regarding primary prevention. Receipt of dietary counseling was categorized by comprehensiveness. Patient quality of life was assessed using the Wisconsin Stone Quality of Life questionnaire (WisQOL). Multivariable linear regression was used to identify predictors of stone-specific health literacy. Results: Of the 2482 participants, 429 (17%) reported prior stone history. Overall accuracy rates ranged from 10% to 98%. Stone patients with comprehensive counseling had the highest scores, driven by significantly better knowledge on oxalate-specific questions ( p < 0.001). Multivariable linear regression showed receipt of comprehensive counseling ( p = 0.032) was an independent predictor of higher primary prevention-specific health literacy. Conclusions: Overall, correct response rates were poor, especially surrounding dietary oxalates. However, kidney stone formers who received more comprehensive counseling demonstrated. greater disease-specific knowledge, serving as a proxy for improved health literacy.

  • Endoscopically visible Randall’s plaques are an independent predictor of future stone events

    by Natalie Meyer, Jean Lee, Victoria Liu, Lejla Pepic, Robert Pearce, Kevin Li, Kevin Shee, Jorge Mena, Justin Ahn, David Bayne, et al.

  • Open Access

    Reducing Opioid Utilization After Ureteroscopy Without Compromising Patient Outcomes in a Statewide Quality Improvement Collaborative

    by Wilson Sui, Suprita Krishna, Russell Becker, Andrew M. Higgins, Caitlin Seibel, Stephanie Daignault-Newton, Golena Fernandez Moncaleano, Hector Pimentel, Brian D. Seifman, David L. Wenzler, et al.


  • Open Access

    Improved 24-hour urine parameters associated with reduced symptomatic kidney stone recurrence

    by Wilson Sui, Heiko Yang, Maria C. Escobar, Feres Maalouf, Pablo Suarez, Thomas Chi, Marshall L. Stoller

    On-treatment 24-h urine testing rates are low outside of tertiary care centers. A common criticism is the paucity of evidence demonstrating the optimization of urinary parameters correlates with reduced stone recurrence. Using standard and novel analytic approaches, we sought to evaluate whether improvements in 24-h urine parameters associated with decreased symptomatic stone recurrence. Kidney stone patients who underwent multiple 24-h urine tests and had an initial parameter abnormality were identified from a prospective database. A novel 24-h urine severity score was calculated at both the initial and subsequent tests and used to stratify patients. Negative binomial regression was used to evaluate the impact of analyte changes on stone recurrence. Two hundred patients met inclusion criteria. Low voided volume, hypercalciuria, hyperoxaluria, hypocitraturia and low pH were identified in 56%, 28%, 40%, 49% and 35% respectively. Patients with hypercalciuria and hypocitraturia who consistently normalized these values showed decreased recurrence (p < 0.001). Increasing initial 24-h urine severity scores associated with increased stone recurrence (0.09, 0.18 and 0.31 stone events per year for the lowest, 25-75th and highest quartiles, p < 0.001). On multivariable analysis, severity score improvement or stabilization was associated with reduced risk of recurrence across all quartiles (RRR 0.319 to 0.591, all p < 0.001). Consistent control of 24-h urine parameters was associated with decreased stone recurrence. Not only did novel 24-h urine composite severity scores based on initial 24-h urines independently predict stone recurrence, improvements in this score over time also predicted decreased recurrence.


  • Open Access

    An intraoperative methylene blue test can guide patient selection for totally tubeless PCNL

    by Jean Lee, Natalie Meyer, Dyandra Parikesit, Brian Dick, Jorge Mena, Tad Manalo, Hunter Flores, Ryan Ferreira, Mustafa Saeed, Melissa Wong, et al.

    Introduction and Objective: Totally tubeless percutaneous nephrolithotomy (PCNL) has been demonstrated to be feasible and safe, particularly for mini-PCNL. Having an objective test to guide patient selection could improve confidence in this practice and facilitate broader adoption. The purpose of this study was to evaluate the utility of an intraoperative methylene blue test to determine candidacy for totally tubeless PCNL. Methods: Adult patients undergoing PCNL at four institutions were included in this study. Patients with prior reconstructive surgery, chronic pain, or requiring ureteral dilation were excluded. After stone clearance, 10 mL methylene blue (MB) dye was injected into the percutaneous access tract. A positive test (“pass”) was defined as visualization of blue dye in the bladder catheter within two minutes of injection. In some standard PCNL cases, totally tubeless management was simulated by placement of a capped nephrostomy tube. Post-operative complications within 7 days were evaluated as the primary outcome. Results: The intraoperative MB test was performed in 91 PCNL cases: 60 mini-PCNLs (16 Fr access) and 31 standard PCNLs (24+ Fr access). Mini-PCNL cases were more likely to pass the MB test compared to standard PCNL cases (75% vs 38.7%, p = 0.001). Of the 45 mini-PCNL subjects who passed, 40 were left totally tubeless, resulting in two minor complications (urinary retention, obstructing ureteral stone fragment). In the standard PCNL cohort, 12 passed the MB test. Five were left totally tubeless and 3 simulated totally tubeless management with capped nephrostomy tubes; one subject had a transient postoperative creatinine elevation, and one required uncapping for steinstrasse. There were no other obstructive or infectious complications, and no surgical reintervention was required. Conclusions: An intraoperative methylene blue test is a simple test with high positive-predictive value to determine candidacy for totally tubeless PCNL in real time for both mini and standard PCNLs.

  • Open Access

    Endoscopically visible Randall’s plaques are an independent predictor of future stone events

    by Natalie R Meyer, Jean Lee, Victoria Liu, Lejla Pepic, Robert Pearce, Kevin Li, Kevin Shee, Jorge Mena, Justin Ahn, David Bayne, et al.

    Introduction and objectives: Randall’s plaques have been long thought to be precursors for kidney stone formation, but how their presence impacts future stone recurrence is not known. The aim of this study was to determine whether patients with endoscopically visible plaques were more likely to have subsequent stone events compared to those without. Methods: The presence of Randall’s plaque in adult patients was prospectively assessed during endoscopic cases as part of the Registry for Stones of the Kidney and Ureter (ReSKU). In each case, the visible Randall’s plaque burden was scored by the attending surgeon as “none,” “minimal,” or “many.” Data regarding stone composition, 24-hour urine tests, and subsequent stone events on follow up were collected. Stone events were defined as patient-reported stone passage or any primary operation for kidney stones; second-look or staged operations were not counted as separate stone events. Results: We identified 673 subjects with a Randall’s plaque assessment, of which 78 had “none,” 306 had “minimal,” and 289 had “many.” Despite having no significant differences in initial stone burden, subjects with visible Randall’s plaque (“minimal” or “many”) had a higher relative risk of stone recurrences after surgery compared to those without (RRR 1.711 (1.121-2.611), p = 0.01). Interestingly, no significant differences in 24-hour urine analytes were observed. Subjects with visible plaque were more likely to have calcium-based stones (84% vs 58%, p < 0.001). Conclusion: The presence of endoscopically visible Randall’s plaque is associated with an increased risk of stone recurrence independent of urine composition.

  • Health Care Spending Associated With Preventative Pharmacologic Therapy for Urolithiasis

    by Wilson Sui, John M. Hollingsworth, Mary K. Oerline, Ryan S. Hsi, Joseph J. Crivelli, Sara L. Best, Vahakn B. Shahinian

    Urolithiasis is among the most expensive urologic conditions from a payer standpoint. Preventative pharmacologic therapy (PPT) can reduce symptomatic recurrences, however, the potential savings from fewer recurrences may be offset by medication costs. This study aimed to evaluate the cost of PPT from the payer perspective. The Medicare-Litholink database was queried for beneficiaries with urolithiasis who had at least one urinary chemistry abnormality. Payments made on their behalf, along with out-of-pocket costs were measured. Payments were compared among amongst three groups using two-part generalized linear models: patients prescribed guideline-concordant PPT who adhered to therapy, those prescribed PPT but did not adhere, and untreated patients. Among 16,329 patients who met inclusion criteria, 30.8% were prescribed PPT. Alkali therapy represented 42.7% of all spending among adherent patients, whereas thiazides and uric acid reducing therapies combined contributed only 3.3%. Out-of-pocket spending on alkali represented 88% of total prescription costs for adherent patients. For patients with hypocitraturia or low pH, adherence to therapy resulted in the lowest mean cost for symptomatic stone events but the highest overall costs due to medication expenses. Conversely, in hypercalciuria and hyperuricosuria, non-adherent patients were the most expensive overall even after multivariable adjustment. Among patients with hypocitraturia and low pH, adherence was the most expensive, driven by medication costs. Conversely, amongst patients with hypercalciuria and hyperuricosuria, non-adherence was costliest. Although PPT can lead to reduced costs due to averted stone events, medication adherence is critical to ensuring these savings are fully realized.